The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole

D A Peura, B Pilmer, B Hunt, R Mody, M C Perez, D A Peura, B Pilmer, B Hunt, R Mody, M C Perez

Abstract

Background: Higher body mass index (BMI) is a recognised risk factor for gastro-oesophageal reflux disease (GERD). Data regarding the impact of BMI on proton pump inhibitor (PPI) therapy are conflicting.

Aim: To assess the impact of BMI on baseline heartburn symptom severity and frequency and response to PPI therapy in patients with non-erosive GERD (NERD) or erosive oesophagitis (EO).

Methods: In post hoc analyses of phase 3 trial data, 621 NERD and 2692 EO patients were stratified by BMI (<25, 25 to <30 and ≥30 kg/m(2) ). NERD patients received either dexlansoprazole MR 30 mg or placebo daily for 4 weeks. EO patients received either dexlansoprazole MR 60 mg or lansoprazole 30 mg for 8 weeks. Symptom frequency and severity were assessed at baseline and subsequently by daily diary.

Results: In both the NERD and EO cohorts, baseline heartburn severity increased with increasing BMI. The impact of PPI therapy on the reduction in heartburn symptom frequency and severity in both NERD and EO patients was similar across BMI categories. EO healing rates in patients treated with dexlansoprazole but not lansoprazole were higher in obese patients compared with those with a BMI <30 kg/m(2) . Differences between the PPIs were small.

Conclusions: The PPIs evaluated in this study reduced the frequency and severity of 24-h heartburn regardless of baseline BMI. In addition, because patients with higher BMI have more severe symptoms at baseline, they may experience greater therapeutic gain with dexlansoprazole (NERD and erosive oesophagitis) and possibly lansoprazole (erosive oesophagitis) treatment.

Trial registration: ClinicalTrials.gov NCT00251693 NCT00251719 NCT00321984.

© 2013 Blackwell Publishing Ltd.

Figures

Figure 1
Figure 1
Frequency of 24-h heartburn-free days during treatment in (a) non-erosive oesophageal reflux disease (NERD) and (b) erosive oesophagitis (EO) patients. Statistically significant differences among BMI categories within treatment group were determined using Kruskal–Wallis test.

References

    1. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710–7.
    1. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17–26.
    1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303:235–41.
    1. El-Serag HB, Graham DY, Satia JA, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol. 2005;100:1243–50.
    1. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199–211.
    1. El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008;53:2307–12.
    1. Nocon M, Labenz J, Jaspersen D, et al. Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study. J Gastroenterol Hepatol. 2007;22:1728–31.
    1. Blondeau K, Boecxstaens V, Van Oudenhove L, et al. Increasing body weight enhances prevalence and proximal extent of reflux in GERD patients ‘on’ and ‘off’ PPI therapy. Neurogastroenterol Motil. 2011;23:724–e327.
    1. Fornari F, Callegari-Jacques SM, Dantas RO, et al. Obese patients have stronger peristalsis and increased acid exposure in the esophagus. Dig Dis Sci. 2011;56:1420–6.
    1. de Vries DR, van Herwaarden MA, Smout AJ, et al. Gastroesophageal pressure gradients in gastroesophageal reflux disease: relations with hiatal hernia, body mass index, and esophageal acid exposure. Am J Gastroenterol. 2008;103:1349–54.
    1. Ayazi S, Hagen JA, Chan LS, et al. Obesity and gastroesophageal reflux: quantifying the association between body mass index, esophageal acid exposure, and lower esophageal sphincter status in a large series of patients with reflux symptoms. J Gastrointest Surg. 2009;13:1440–7.
    1. Kuper MA, Kramer KM, Kirschniak A, et al. Dysfunction of the lower esophageal sphincter and dysmotility of the tubular esophagus in morbidly obese patients. Obes Surg. 2009;19:1143–9.
    1. Schneider JH, Kuper M, Konigsrainer A, et al. Transient lower esophageal sphincter relaxation in morbid obesity. Obes Surg. 2009;19:595–600.
    1. Wu JC, Mui LM, Cheung CM, et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology. 2007;132:883–9.
    1. El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure. Gut. 2007;56:749–55.
    1. Fletcher J, Derakhshan MH, Jones GR, et al. BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy. Gut. 2011;60:442–8.
    1. Heading RC, Monnikes H, Tholen A, et al. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol. 2011;11:52.
    1. Sheu BS, Cheng HC, Chang WL, et al. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis. Am J Gastroenterol. 2007;102:2387–94.
    1. Sheu BS, Chang WL, Cheng HC, et al. Body mass index can determine the healing of reflux esophagitis with Los Angeles Grades C and D by esomeprazole. Am J Gastroenterol. 2008;103:2209–14.
    1. Pace F, Coudsy B, DeLemos B, et al. Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. Eur J Gastroenterol Hepatol. 2011;23:845–51.
    1. Labenz J, Armstrong D, Zetterstrand S, et al. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis–results from the EXPO study. Aliment Pharmacol Ther. 2009;29:959–66.
    1. Talley NJ, Armstrong D, Junghard O, et al. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2006;24:371–6.
    1. Carpiuc KT, Mody R, Perez MC, et al. Assessing the impact of body mass index (BMI) on the efficacy of proton pump inhibitors (PPIs) in GERD: a review of the literature. Am J Gastroenterol. 2011;106:S413.
    1. Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009;29:1261–72.
    1. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation–results from two randomized controlled studies. Aliment Pharmacol Ther. 2009;29:731–41.
    1. Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease–where next? Aliment Pharmacol Ther. 2005;22:79–94.
    1. Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut. 2012;61:501–6.
    1. Kinoshita Y, Ashida K, Hongo M. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2011;33:213–24.
    1. Dickman R, Boaz M, Aizic S, et al. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil. 2011;17:387–94.
    1. Labenz J, Armstrong D, Zetterstrand S, et al. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis–results from the maintenance phase of the EXPO study. Aliment Pharmacol Ther. 2009;29:1165–71.
    1. Jacobson BC. Body mass index and the efficacy of acid-mediating agents for GERD. Dig Dis Sci. 2008;53:2313–7.
    1. Vakily M, Zhang W, Wu J, et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009;25:627–38.
    1. Fass R, Quan SF, O'Connor GT, et al. Predictors of heartburn during sleep in a large prospective cohort study. Chest. 2005;127:1658–66.
    1. Fass R, Johnson DA, Orr WC, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011;106:421–31.
    1. Ribolsi M, Emerenziani S, Petitti T, et al. Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responders to proton pump inhibitors. Dig Liver Dis. 2012;44:549–54.
    1. Frazzoni M, De Micheli E, Zentilin P, et al. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther. 2004;20:81–8.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다